²Î¿¼ÎÄÏ×/References:
[1] Ministrini S,Carbone F,Montecucco F.Updating concepts on atherosclerotic inflammation: from pathophysiology to treatment[J].Eur J Clin Invest,2021,51(5):e13467.
[2] Casula M,Montecucco F,Bonaventura A,et al.Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases[J].Vascul Pharmacol,2017:1-12.
[3] Wilensky RL,Macphee CH.Lipoprotein-associated phospholipase A(2)and atherosclerosis[J].Curr Opin Lipidol,2009,20(5):415-420.
[4] Zhao YF,Zhang XJ,Chen XY,et al.Neuronal injuries in cerebral infarction and ischemic stroke: from mechanisms to treatment(Review)[J].Int J Mol Med,2022,49(2):15.
[5] ÖÓµÏ,ÕÅÊææÃ,ÎⲨ.¡¶Öйú¼±ÐÔȱѪÐÔÄÔ×äÖÐÕïÖÎÖ¸ÄÏ2018¡·½â¶Á[J].ÖйúÏÖ´úÉñ¾¼²²¡ÔÓÖ¾,2019,19(11):897-901.
[6] Coveney S,McCabe JJ,Murphy S,et al.Anti-inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack[J].Cochrane Database Syst Rev,2020,5(5):CD012825.
[7] Wolf D,Ley K.Immunity and inflammation in atherosclerosis[J].Herz,2019,44(2):107-120.
[8] Dharmakidari S,Bhattacharya P,Chaturvedi S.Carotid artery stenosis: medical therapy, surgery, and stenting[J].Curr Neurol Neurosci Rep,2017,17(10):77.
[9] Pedro-Botet J.CEDA,inflammation,new therapeutic approaches,arteriosclerosis e inflamación.Nuevosenfoquesterapéuticos[J].Med Clin(Barc),2020,155(6):256-262.
[10] Pathak A,Agrawal A. Evolution of C-reactive protein[Z], 2019: 943.
[11] Zlibut A,Bocsan IC,Agoston-Coldea L.Pentraxin-3 and endothelial dysfunction[J].Adv Clin Chem,2019,91:163-179.
[12] Carrizzo A,Lenzi P,Procaccini C,et al.Pentraxin 3 induces vascular endothelial dysfunction through a p-selectin/matrix metalloproteinase-1 pathway[J].Circulation,2015,131(17):1495-1505; discussion 1505.
[13] Adam CA, ÿðþ ‰C alaru DL,Prisacariu C,et al.Novel biomarkers of atherosclerotic vascular disease-latest insights in the research field[J].Int J Mol Sci,2022,23(9):4998.
[14] Yan XJ,Gao J,Tang M,et al.Combined assessment of elevated plasma lipoprotein-associated phospholipase a2 and plaque enhancement improved accuracy in the risk of acute ischemic stroke in patients with intracranial artery stenosis[J].J Stroke Cerebrovasc Dis,2021,30(12):106103.
[15] ²Ü¾².ѪÇåÖ¬µ°°×Ïà¹ØÁ×֬øA2ÔÚ¼±ÐÔȱѪÐÔÄÔ×äÖаéÄÔ¶¯ÂöÏÁÕÖеÄÁÙ´²¼ÛÖµ[D].ºÏ·Ê:°²»ÕÒ½¿Æ´óѧ,2021.
[16] Zhang S,Huang S,Hu D,et al. Biological properties and clinical significance of lipoprotein-associated phospholipase a2 in ischemic stroke[Z], 2022: 3328574.
[17] Bonnefont-Rousselot D.Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques[J].Ann Pharm Fr,2016,74(3):190-197.
ÏàËÆÎÄÏ×/References:
[1]°üÕý¾ü,ÁõÁÕ.¼±ÐÔÄÔ¹£ËÀ»¼ÕßѪÇåÄòËáˮƽÓë¾±¶¯ÂöÖàÑùÓ²»¯µÄ¹ØϵÑо¿[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2015,22(03):160.
[2]°×ÎÄæÃ,ÑîÀöÈÙ,ÂÀÀûÓ¢,µÈ.¶à¸öΣÏÕÒòËؾۼ¯Óë¼±ÐÔȱѪÐÔÄÔ×äÖл¼Õß³öÔº½á¾Ö²»Á¼µÄ¹Øϵ[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2015,22(02):71.
[3]³Â´äÈÙ,ÕÔÕñ¹ú,ÖÜæÂ,µÈ.ÇáÖжȼ±ÐÔÄÔ¹£ËÀMRIÖ¸µ¼Ï³¬Ê±¼ä´°¾²ÂöÈÜ˨ÖÎÁƵÄÑо¿[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2014,21(06):330.
[4]µ«±ÏÌÃ,ÅíСÏé,³ÂСÆæ,µÈ.¼±ÐÔȱѪÐÔÄÔ×äÖÐʱ¼ä´°ÄڵĶ¯¾²ÂöÈÜ˨·Ö²ãÖÎÁƵĶԱÈÑо¿[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2014,21(06):334.
[5]×ÚÑåÎä,²ÌÁøÑà,ÕÅÑÒ.Éñ¾½éÈëÁªºÏ°¢¼ÓÇú°à¶Ô¼±ÐÔȱѪÐÔÄÔ×äÖл¼ÕßѪÇåFIB,D-D±í´ïˮƽµÄÓ°Ïì[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2022,29(04):365.[doi:10.3969/j.issn.1007-0478.2022.04.012]
[6]À·å,ÀîÕñ»ª,ÁõÀö¾ê.¼±ÐÔȱѪÐÔÄÔ×äÖл¼ÕßѪÇåSurvivin,Hepc25ˮƽ±ä»¯¼°ÆäÁÙ´²ÒâÒå[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2022,29(05):432.[doi:10.3969/j.issn.1007-0478.2022.05.007]
¡¡Li Haifeng*,Li Zhenhua,Liu Lijuan*..Changes in serum Survivin and Hepc25 levels in patients with acute ischemic stroke and their clinical significance[J].Stroke and Nervous Diseases,2022,29(03):432.[doi:10.3969/j.issn.1007-0478.2022.05.007]
[7]ÇØÑÅöÎ ÈÎÕ¼ÔÆ Àî½Ü Ðí¶¬»ª Ò¶ÉòÔç ³Â½¯éª.Willis»·ÍêÕûÐÔºÍÄÔ°×Öʱ仯¶Ô¼±ÐÔȱѪÐÔÄÔ×äÖл¼ÕßÉñ¾¹¦ÄÜȱËð¼°Ô¤ºóµÄÓ°Ïì[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2023,30(03):259.[doi:10.3969/j.issn.1007-0478.2023.03.005]
¡¡Qin Yaxin,Ren Zhanyun,Li Jie,et al.Effects of Willis ring integrity and white matter changes on neurological deficit and prognosis in patients with acute ischemic stroke[J].Stroke and Nervous Diseases,2023,30(03):259.[doi:10.3969/j.issn.1007-0478.2023.03.005]
[8]¹ËÁÁÁÁ Íõ½¨·æ ÇÇöÎ Õű£³¯ ¸µ¹ú»Ý.¼±ÐÔȱѪÐÔÄÔ×äÖл¼Õß¾²ÂöÈÜ˨ǰºóSCUBE1ˮƽµÄ±ä»¯¼°ÆäÓëÔ¤ºó²»Á¼µÄÏà¹ØÐÔ·ÖÎö[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2023,30(03):265.[doi:10.3969/j.issn.1007-0478.2023.03.006]
¡¡Gu Liangliang*,Wang Jianfeng,Qiao Xin*,et al.Changes of SCUBE1 levels after thrombolytic therapy in patients with acute ischemic stroke and its correlation with prognosis[J].Stroke and Nervous Diseases,2023,30(03):265.[doi:10.3969/j.issn.1007-0478.2023.03.006]
[9]ÍõÇïÀö¡þÑîÐ˵¤¡þÕź½¡þÀî¹ú·æ¡þÁõ³¿·Æ.°éÓë²»°éÄÔ¶¯ÂöѪ¹Ü±Ú¸Æ»¯µÄ¾±¶¯ÂöÖàÑùÓ²»¯»¼ÕßµÄÁÙ´²ÌØÕ÷¼°Ô¤ºó·ÖÎö[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2023,30(03):278.[doi:10.3969/j.issn.1007-0478.2023.03.009]
¡¡Wang Qiuli,Yang Xingdan,Zhang Hang,et al.Differences in clinical characteristics and prognosis of patients with carotid atherosclerosis with and without cerebral artery vascular wall calcification[J].Stroke and Nervous Diseases,2023,30(03):278.[doi:10.3969/j.issn.1007-0478.2023.03.009]
[10]¹¨ººÏÍ,ׯÔó΢,ÀîÊöÌÒ,µÈ.ÇòÄÒµ¼Òýµ¼¹ÜÔÚÀÏÄê¼±ÐÔȱѪÐÔÄÔ×äÖл¼Õßȡ˨ÖÎÁÆÖеÄ×÷ÓÃ[J].×äÖÐÓëÉñ¾¼²²¡ÔÓÖ¾,2024,31(01):73.[doi:10.3969/j.issn.1007-0478.2024.01.012]